|
|
| | 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-tri(methyl-d3)-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- Basic information |
| Product Name: | 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-tri(methyl-d3)-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- | | Synonyms: | 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-tri(methyl-d3)-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)-;16:0 PC-d9;[D9]-1,2-Dipalmitoyl-sn-glycero-3-phosphocholine | | CAS: | 77165-56-1 | | MF: | C40H80NO8P | | MW: | 734.05 | | EINECS: | | | Product Categories: | | | Mol File: | 77165-56-1.mol | ![3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-tri(methyl-d3)-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- Structure](CAS/20211123/GIF/77165-56-1.gif) |
| | 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-tri(methyl-d3)-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- Chemical Properties |
| storage temp. | -20°C | | solubility | Acetonitrile: Methanol: (1:1): Slightly Soluble: 0.1-1 mg/ml Methanol: Sparingly Soluble: 1-10 mg/ml | | form | powder | | color | White to off-white | | InChIKey | KILNVBDSWZSGLL-IFKPPQQBSA-N | | SMILES | [H][C@@](COP([O-])(OCC[N+](C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)(OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-tri(methyl-d3)-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- Usage And Synthesis |
| Uses | DPPC-d9-1 is the deuterium labeled DPPC. DPPC (129Y83) is a zwitterionic phosphoglyceride that can be used for the preparation of liposomal monolayers[1]. DPPC-liposome serves effectively as a delivery vehicle for inducing immune responses against GSL antigen in mice[2]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110 [2] Miller AD. Delivery of RNAi therapeutics: work in progress. Expert Rev Med Devices. 2013 Nov;10(6):781-811. DOI:10.1586/17434440.2013.855471 [3] Akiko Uemura, et al. Induction of immune responses against glycosphingolipid antigens: comparison of antibody responses in mice immunized with antigen associated with liposomes prepared from various phospholipids. J Vet Med Sci. 2005 Dec;67(12):1197-201. DOI:10.1292/jvms.67.1197 [4] CANAY EGE Ka Y C L. Insertion of Alzheimer’s A beta 40 peptide into lipid monolayers.[J]. Biophysical journal, 2004, 87 3: 1732-1740. DOI: 10.1529/biophysj.104.043265 [5] SUKIT LEEKUMJORN Amadeu K S. Molecular simulation study of structural and dynamic properties of mixed DPPC/DPPE bilayers.[J]. Biophysical journal, 2006, 90 11: 3951-3965. DOI: 10.1529/biophysj.105.076596 [6] V K KALRA G S S S C Sikka. Transport of amino acids in gamma-glutamyl transpeptidase-implanted human erythrocytes.[J]. The Journal of Biological Chemistry, 1981, 256 11: 5567-5571. |
| | 3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-tri(methyl-d3)-10-oxo-7-[(1-oxohexadecyl)oxy]-, inner salt, 4-oxide, (7R)- Preparation Products And Raw materials |
|